Short Hills, NJ – According to filings with the U.S. Securities and Exchange Commission, Areteia Therapeutics/AreteiaTx is raising $350,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Jorge Bartolome played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Areteia Therapeutics/AreteiaTx
Areteia Therapeutics is a new biotechnology company committed to putting asthma patients in better control of their disease and back in control of their lives with the first potential oral drug for eosinophilic asthma. Today, our team is focused on a single goal: To develop the first oral drug for eosinophilic asthma. Our global development team brings together experts from Knopp Biosciences, which previously developed dexpramipexole, and Population Health Partners, whose employees and executives led eight drug approvals involving 21 clinical trials and 91,000 patients worldwide in their earlier work at The Medicines Company. Areteia Therapeutics (areteiatx.com) is a clinical stage biotechnology company committed to putting asthma patients in better control of their disease and lives by developing the first potential oral drug for eosinophilic asthma. Areteia will conduct late-stage development including Phase 3 clinical trials of dexpramipexole in partnership with Population Health Partners development unit, Validae Health. Areteia will be led by Chief Executive Officer, Jorge Bartolome, with a Board of Directors including Michael Bozik, M.D., President, Biohaven Labs, and the former President and Chief Executive Officer of Knopp; Adam Koppel, M.D., PH.D., Managing Director of Bain Capital Life Sciences; Ian Read, Partner at Population Health Partners and the former Chairman and Chief Executive Officer of Pfizer; and Paul Berns, Managing Director at Arch Ventures.

To learn more about Areteia Therapeutics/AreteiaTx, visit http://areteiatx.com/

Contact:
Jorge Bartolome, Chief Executive Officer
212-993-3113
jorge.bartolome@areteiatx.com
https://www.linkedin.com/in/jorgebartolome/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved